BlueBird Bio, Inc.: Series C $30M

Posted in I - Series C, Q - 2Q11, R - NORTH EAST, X - Gene Therapy, X - Stem Cell, XX - MA

BlueBird Bio (Cambridge, MA) a clinical-stage developer of innovative stem cell-based gene therapies for severe genetic disorders, closed a $30M Series C financing. Participants include Arch Venture Partners, Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group.

Dec

2010

Ceregene, Inc.: Series D $11.5M

Posted in I - Series D, Q - 4Q10, R - WEST, X - Alzheimer's, X - Gene Therapy, X - Parkinson's, XX - CA

Ceregene (San Diego, CA) a clinical-stage biopharmaceutical company focused adeno-associated virus vector-based gene therapy for Parkinson’s and Alzheimer’s disease, closed a $11.5M Series D financing. Participants include Hamilton BioVentures, Alta Partners, MPM Capital and Investor Growth Capital.

Mar

2010

Genetix Pharmaceuticals, Inc.: Series B $35M

Posted in I - Series B, Q - 1Q10, R - NORTH EAST, X - ALD, X - Gene Therapy, XX - MA

Genetix Pharmaceuticals (Cambridge, MA) a clinical-stage gene therapy company whose lentiviral technology is focused upon severe genetic disorders such as adrenoleukodystrophy and beta-thalassemia, closed a $35M Series B financijng. Participants include Third Rock Ventures, Genzyme Ventures, TVM Capital, Forbion and Easton Capital.

Nov

2009

Celladon, Inc.: Series C $21.8M

Posted in I - Series C, Q - 3Q09, R - WEST, X - Cardiology, X - Gene Therapy, XX - CA

Celladon (La Jolla, CA) a clinical-stage company focused on gene therapy for congestive heart failure, closed a $21.8M Series C financing. Participants include Enterprise Partners Venture Capital, Venrock and Johnson & Johnson Dev Corp.

to top of page...